Risk for Corneal Injury in Critically Ill Patients and Effect of Nursing Interventions for Its Prevention: Randomized Controlled Trial
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 360
- 试验地点
- 2
- 主要终点
- Keratitis
研究概览
简要总结
The purpose of the study is find out the better measure to achieve corneal protection in an Intensive Care Unit.
详细描述
Critically ill patients are at higher risk for corneal injury and the mechanisms responsible for ocular lubrication and protection can be compromised. However, the literature diverges on which is the best clinical practice for treatment. There is a scale for assessing the risk for corneal injury. Thus, the general objective of this study was to evaluate the risk for developing corneal injury in critically ill patients and the effectiveness of three types of interventions: eye gel, eyedrops and polyethylene film, compared to the control group in its prevention. The specific objectives were: verify the most effective intervention for the prevention of corneal injury from the available literature and provided by: eye gel, eyedrops and polyethylene film compared to the control group who received eye care through randomized controlled clinical trial. Patients and methods: This study was a randomized controlled trial to determine the best care for the prevention of corneal injury from those available on the market (eye drops, eye gel and polyethylene film), compared to a control group (eye care) in the period from 09/07/2013 to 03/15/2014 .
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Factorial
- 主要目的
- Prevention
- 盲法
- Single (Investigator)
入排标准
- 年龄范围
- 18 Years 至 93 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Ramsay sedation scale 5 or 6
- •Glasgow coma scale lower than 7
- •Use of oxygen therapy by facial device above 6 liters per minute or mechanical ventilation
- •Blink reflex less than 5 times per minute or ocular globe exposure
排除标准
- •Less than 48 hours in Intensive Care Unit
结局指标
主要结局
Keratitis
时间窗: Five days
Presence of keratitis visible with a cobalt light ophthalmoscope and fluorescein eye drop.
次要结局
未报告次要终点
研究者
Andreza Werli Alvarenga
RN, MD, PhD
Hospital Risoleta Tolentino Neves
